WO2006059145A2 - Transgenic animals with reduced major urinary protein production - Google Patents
Transgenic animals with reduced major urinary protein production Download PDFInfo
- Publication number
- WO2006059145A2 WO2006059145A2 PCT/GB2005/004674 GB2005004674W WO2006059145A2 WO 2006059145 A2 WO2006059145 A2 WO 2006059145A2 GB 2005004674 W GB2005004674 W GB 2005004674W WO 2006059145 A2 WO2006059145 A2 WO 2006059145A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- umup
- complex
- animal
- animals
- transgenic animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
Definitions
- the present invention relates to a transgenic animal having substantially reduced major urinary protein (uMUP) production.
- the present invention also relates to methods of producing such animals, and to the uses of such animals.
- uMUPs major urinary proteins
- Mouse urine contains a high concentration of proteins termed major urinary proteins (uMUPs), whose only known functions are in chemical signalling. These small proteins bind a wide-range of male-specific volatile pheromones (Bacchini et al. 1992; Robertson et al. 1993) and elicit a slow release of these volatiles from the urine scent marks that males deposit throughout their territory (Hurst et al. 1998). These male- specific volatiles are used in competitive communication between males, stimulating aggression (Novotny et al. 1985), attraction (Humphries et al. 1999; Mucignat-Caretta & Caretta 1999) or aversion (Novotny et al.
- Involatile uMUPs and their bound ligands also play a more direct role in signalling. Scent marks deposited in the environment can only provide information about the owner if the scent contains a stable and persistent signal of owner identity. Genetically heterogeneous wild mice express many uMUP polymorphic variants, each individual expressing around 7 to 14 variants (Payne et al 2001). The combinatorial diversity of uMUPs is thus extremely high (potentially as great as for MHC). The inventors have shown that uMUPs provide genetically-determined individuality signatures in the urine scent marks of male mice (Hurst et al. 2001b).
- VNO vomeronasal organ
- electrophysiological recordings in freely behaving laboratory mice investigating an anaesthetised conspecific reveal that neurones in the accessory olfactory bulb (which receives input from the VNO) are activated only when the nose makes direct contact with the source of social odours (Luo et al. 2003).
- uMUPs and their bound ligands are the most likely candidates for delivering social identity signals to VNO receptors, although no one has yet been able to examine their role during direct interactions between conspecif ⁇ cs rather than isolated scents.
- MUPs have evolved to bind volatile pheromones, are by far the most prevalent involatile components of mouse urine, comprising more than 99% of urinary proteins (Humphries et al. 1999), exhibit sufficient complexity and stability (Beynon et al., 2001) and have already been shown to provide the ownership signal in male scent marks.
- mice Learning this association may be essential to allow mice to recognise both the sex and identity of a conspecific from their volatile scents alone.
- Female mice that have never previously encountered the scents of adult males show an innate attraction to male scents they are able to contact.
- na ⁇ ve females show no such innate attraction if contact is prevented and they detect only airborne volatiles (Moncho- Bogani et al. 2002).
- females learn an association between the involatile and volatile components and, subsequently, are attracted to the volatile components of male scents alone.
- a similar mechanism may apply to male recognition of females.
- Male mice emit ultrasonic (7OkHz) courtship vocalizations specifically in response to females or their scents.
- mice Many genes influence the volatile scents produced by animals, especially those of the highly polymorphic MHC (e.g. mice: Yamazaki et al. 1979; rats: Singh et al 1987; humans: Wedekind et al. 1997, Jacob et al. 2002).
- Laboratory studies utilizing MHC congenic strains have confirmed that both mice and rats are able to discriminate airborne urinary odours when donors differ genetically only at alleles within the MHC region (Singh et al. 1987; Carroll et al. 2002). These odours promote MHC disassortative mating (Potts et al. 1991) and kin recognition (Manning et al 1992) between interacting mice.
- MHC is neither sufficient nor necessary for the recognition of individual scent mark owners. Mice learn to recognise the volatile odours of familiar neighbour competitors resulting from both MHC and genetic background, which induces prolonged investigation of their scent marks; but once closely investigated MHC-associated odours induce no further response (Hurst et al, to be published 2005). This is in contrast to uMUP-associated scents, which on close investigation allow recognition and countermarking of scents from specific individual neighbours.
- MHC-associated odours The molecular basis of MHC-associated odours is not known, but appears to involve a complex mixture of volatile metabolites bound and released by urinary proteins (Singer et al 1993, 1997). It is not known whether the urinary proteins involved are fragments of MHC molecules themselves, or are uMUPs.
- the "carrier hypothesis" proposes that soluble fragments of MHC class I and class II molecules in urine differentially bind volatile metabolites in the antigen-binding groove once the peptide that is normally bound tightly in this groove is lost during the fragmentation process. Further proteolysis of the fragments would then lead to release of the volatiles.
- MHC specificity of odours is thus determined by the highly polymorphic binding characteristics of the antigen-binding groove. How low molecular weight volatiles could be specifically bound to MHC protein fragments that normally bind peptides is unclear though (Singer et al. 1997). By contrast, the central calyx of uMUPs is designed to bind small odorant molecules and uMUPs are present in considerably greater concentration than MHC fragments in urine (Beynon et al. 2001). It is also well established that many physiological traits are genetically associated with the MHC and are likely to influence metabolites (e.g. Ivanyi 1978).
- MHC-based developmental and physiological variations give rise to distinct volatile profiles (Boyse et al. 1987) which are then bound and released by uMUPs (Beynon & Hurst 2004).
- MHC-associated odours have different implications for the potential importance of MHC-associated odours in communication.
- the carrier hypothesis is correct, there is a specific and separate mechanism for chemical communication of MHC type in which involatile MHC fragments may deliver MHC-specific information to the VNO independently of information carried by uMUPs.
- volatile ligands reflect general physiological traits that are influenced by many genetic and environmental factors and will provide much less specific information about MHC type. It would also mean that two highly polymorphic multigene complexes inherited independently on separate chromosomes act together to determine the main genetic basis of an individual's volatile and involatile urinary profile. The capacity for unique combinations of these components is considerable.
- an animal having substantially reduced uMUP production for example for use in laboratories, animal houses, animal breeding centres, etc.
- animals which are hypoallergenic One of the main causes of animal allergy, particularly in laboratories and animal houses, etc., is lipocalins.
- lit/lit mouse which is a growth hormone deficient strain.
- the lit/lit mouse is a dwarfed mouse, and, along with a number of other abnormalities, shows approximately 1% of normal adult uMUP levels.
- Duncan et al., (1988) describes a survey of uMUPs in laboratory mice, in particular in the substrain BALB/cJPt.
- BALB/cJPt has two uMUP phenotypes, one of which, designated the "null phenotype" produces less uMUPS than the other. This mouse is not a true "null-MUP" because it does still produce a substantial amount of uMUPs.
- transgenic animal from whose genome a uMUP complex has been inactivated or deleted, wherein said inactivation or deletion substantially reduces the production or secretion of uMUPs.
- uMUP is used herein to mean the major urinary proteins found in mouse urine and the equivalent proteins found in the urine of other animals, such as, but not limited to the ⁇ 2u globulins found in rat urine.
- the transgenic animal according to the invention may be any animal, preferably a non- human animal, more preferably a non-human mammal, more preferably a rodent, especially a mouse or a rat. Mice are especially preferred. Any mouse strain may be used to produce the transgenic animal of the present invention, including in-bred, out- bred, hybrid, mutant (natural mutation), transgenic and congenic strains and wild- derived mice. Preferred strains include 129Sv/Ev and C57B16/J.
- wild-derived animal includes animals captured from the wild or animals bred in captivity for one or more generations from animals captured from the wild.
- substantially reduction of uMUP production means that the transgenic animal has less uMUPs in its urine than is found in wild-type animal urine.
- the wild-type animal is of the same species, gender and age as the transgenic animal, and is preferably of the same strain as the transgenic animal.
- the term preferably means the transgenic animal's urine contains less than 10% of the level of uMUPs found in the urine of a wild-type animal, preferably less than 5%, more preferably less than 1%, more preferably less than 0.5%, more preferably less than 0.1%, most preferably less than 0.01%.
- Most preferably uMUP production is reduced to such a degree that uMUPs cannot be detected in non-concentrated urine by standard techniques such as isoelectric focussing on acrylamide gels immunoassay or mass spectrometry.
- Wild-type animal means a common example of an animal that exhibits similar characteristics to those found naturally. In particular it means a non-mutant and non- transgenic animal. The term may apply to wild animals or laboratory strains. It is a term that is clear to those skilled in the art.
- the wild-type mouse is preferably considered to be a mouse strain derived from (1) C57-related strains (e.g. C57BL/6, C57BL/10, C57BR, C58, C57BLKS and related strains); (2) Castle's mice (e.g. DBA, CBA, C3H, BALB, 129-related strains, A, AKR, NZ and related strains); (3) Swiss mice (e.g. ICR, SWR, SWJ, SJL, FVB, NIH, NMRI, NOD, NOR, HLS and related strains); (4) strains derived from colonies from China and Japan (e.g.
- strains derived from wild mice e.g. SPRET, CAST, CASA, PANCEVO, MOL-related strains
- other inbred strains e.g. RIII, RBC, CPB
- outbred strains e.g. ICR, CD-I, MFl, CF-I, Swiss, CFW, SKHl, PGP, BK
- the wild-type rat is preferably considered to be a rat strain derived from (1) an inbred strain (e.g. PVG, Lewis, Fischer, Nude, Brown Norway, SHR, WKY, Noble, Copenhagen, BDIX, Buffalo and related strains) or (2) an outbred strain (e.g. CD, Wistar, Sprague Dawley, Long Evans, Zucker).
- concentration of uMUPs in the urine of mice is usually between lmg/ml and 50 mg/ml for males and between 0.2mg/ml and 20mg/ml for females when uMUP concentration is measured by any protein assay.
- a male transgenic mouse according to the invention preferably has a urine uMUP concentration of less than lmg/ml, more preferably less than 0.5 mg/ml, more preferably less than 0. lmg/ml, even more preferably less than 0.05 mg/ml, most preferably less than 0.0 lmg/ml.
- a female transgenic mouse according to the invention preferably has a urine uMUP concentration of less than 0.2mg/ml, more preferably less than 0. lmg/ml, more preferably less than 0.05mg/ml, even more preferably less than 0.025 mg/ml, most preferably less than 0.01mg/ml.
- the relative quantity of uMUP excreted by these uMUP-null mice was significantly less than the mean uMUP concentration of urine from normal wild-type BALB/cAn mice but varied between individuals.
- the relative uMUP concentration of male uMUP-null mice was approximately 35% of mean values for normal wild-type BALB/cAn males (range 23 53%) while uMUP concentration of female uMUP-null mice was approximately 19% of mean values for normal wild-type BALB/cAn females (range 12 22%).
- the transgenic animal is phenotypically identical to a wild-type animal except for the reduction or absence of uMUP production.
- the transgenic animal has no physiological or morphological abnormalities. By ensuring that the transgenic animal has no physiological or morphological abnormalities it means that the animal can be used in research.
- uMUP complex substantially all uMUPs are encoded by a single gene cluster. This is known herein as the uMUP complex. In mice this complex is found on chromosome 4. By inactivating, preferably by deleting, this single complex uMUP production is substantially reduced. Similar complexes are found in other animals, in particular, the rat, in which the equivalent proteins are termed ⁇ 2u globulins encoded by genes on chromosome 5.
- Inactivation of the uMUP complex is taken to mean preventing the expression of functional uMTJPs from the complex. This can be done, for example, by deleting the complex or by replacing it with a non-functional complex, or by mutating the complex so that expression of functional uMUPs is prevented.
- the uMUP complex is inactivated by deleting the entire complex. It is preferable to delete the complex so that there is no chance of an inactivated complex reverting to an active form, from which the expression of functional uMUPs is possible.
- a functional uMUP is a uMUP that is able to bind pheromones and/or other ligands involved in the transmission of information between animals by scent and is allergenic.
- An inactivated uMUP does not bind pheromones and/or other ligands and/or is not allergenic.
- the inactivated uMUP has neither function.
- the complex can be removed by any known method. For example it can be removed by using a single targeting vector with homology arms which embrace the complete uMUP complex. Alternatively, two vectors may be used which flank the uMUP complex, wherein when the two vectors combine, the uMUP complex is deleted.
- the vector or vectors may contain a marker, so that cells which have been successfully targeted by the vector may be identified and selected.
- the uMUP complex can be mutated to prevent expression of functional uMUPs.
- Methods for mutating the uMUP complex will be apparent to those skilled in the art.
- the uMUP complex In mice, the uMUP complex is approximately IMbp in size. The complex is found between nucleotides 59224905 and 60414792bp. The first uMUP gene is MUP4 at
- the uMUP complex is flanked by regions which can be used by targeting vectors for removal of the complex.
- a Tscot region is found between nucleotides 59173225 and 59183155.
- a zinc finger gene Zfp37 is found between 60517046 and 60535864bp. (All taken from the Ensembl database as of 15 November 2004.)
- the numbering of the nucleotides given above may change as the nucleotide sequence is refined. This would be clear to one skilled in the art.
- the uMUP complex is preferably found between the 3' end of the Tscot region and the 5' end of the Zfp37 gene.
- the sequence of the Tscot region is provided in SEQ ID No. 1.
- the sequence of the Zfp37 gene is provided in SEQ ID No. 2.
- the equivalent complex is in the region of 78.4 Mbp on chromosome 5.
- a Tscot region is found at 78.05Mbp.
- a zinc finger gene Zfp37 is found at 79.0Mbp.
- the present invention also provides a method of producing a transgenic animal which has substantially reduced uMUP production, comprising these steps of: A) Providing embryonic stem cells comprising an intact uMUP complex;
- the transgenic animal produced by this method may be heterozygous or homozygous for the inactivated uMUP complex.
- the method further includes the step of breeding the resulting offspring with similar offspring in order to produce stable animals which are homozygous or heterozygous for the inactivated uMUP complex.
- the one or more vectors used in the above methods may inactive the uMUP complex by any known method. Preferably the vectors delete the uMUP complex.
- the one or more vectors may be any vectors which target the uMUP complex, or areas which flank it.
- the one or more vectors preferably comprise a single targeting vector with homology arms, which embrace the complete uMUP complex.
- two vectors which flank the uMUP complex may be used.
- the vectors flanking the complex may preferably comprise LoxP, and bring about Cre- mediated recombination to eliminate the uMUP complex.
- the vectors preferably target the Tscot and Zfp37 regions which flank the uMUP complex.
- the vectors preferably target the regions between the Tscot and Zfp37 regions and the uMUP complex.
- vectors which insert a sequence or which bring about mutations throughout the entire region may be used.
- vectors which insert a sequence or which bring about mutations throughout the entire region may be used.
- the method of producing a transgenic animal according to the invention may further comprise the step of inactivating any residual uMUP sites which are not part of the uMUP complex.
- the invention further provides vectors for use in the method of the invention.
- the method provides a single targeting vector, with homology arms which embrace the complete uMUP complex.
- the vector is pMupsTVl as described in the example section below.
- the vectors flanking the complex preferably comprise LoxP, and bring about Cre-mediated recombination to eliminate the uMUP complex.
- the vectors include vectors known to one skilled in the art which may be used to inactivate, especially delete, the uMUP complex.
- the vectors include a marker to enable cells successfully targeted with a vector to be identified and selected.
- the vectors preferably include part of a gene, such as the HPRT gene.
- the HPRT gene is reassembled and may be identified. As a result the cells may be selected for in culture.
- the present invention also provides animals created by the methods of the invention.
- the invention provides animals which are heterozygous for an inactivated uMUP complex, animals which are homozygous for an inactivated uMUP complex, and all generations of animals which have been bred from animals created by the methods of the invention, or from animals created by the methods of the invention which have been crossed with wild-type animals or wild-derived animals, for example, F 1 , F 2 , F 3 , and F 4 generations.
- Such animals include animals bred by crossing an animal created by the methods of the invention with another animal created by the methods of the invention.
- Such animals also include animals bred by crossing an animal created by the methods of the invention with a wild-type animal, and further generations therefrom.
- animals which have been bred from an animal that is homozygous for an inactivated uMUP complex are preferred. Such animals have not been exposed to a maternal uMUP complex. Also preferred are animals that have been bred from an animal that is heterozygous for an inactivated uMUP complex.
- the present invention also provides an embryonic stem cell that is heterozygous or homozygous for an inactivated uMUP complex.
- Methods for producing such embryonic stem cells from the transgenic animals of the present invention are well known to those skilled in the art.
- the embryonic stem cell is a non-human stem cell, more preferably a rodent (e.g. mouse or rat) embryonic stem cell.
- testing methods preferably include the step of analysing a sample from a transgenic animal, in particular a urine, tissue or blood sample.
- the sample may be tested for uMUP concentration, for RNA produced in the expression of uMUPS, or for the presence of an active or inactivated uMUP complex in the animal's DNA.
- Such testing may be carried out by any method known to one skilled in the art, but particularly by methods such as southern blot analysis of DNA and protein chemistry analysis of urine, such as immunochemical, mass spectrometry and photometric analysis.
- Tests may also include testing urine for ligand release rates. Ligands normally bound by uMUPs will be released from the urine of a transgenic animal having substantially reduced uMUP production faster than from wild-type animal urine.
- transgenic animal having substantially reduced uMUP production in behavioural studies.
- the transgenic animal used in such studies is homozygous for the inactivated uMUP complex, but a heterozygous animal may also be used.
- the transgenic animal used in the behavioural studies may also be an animal bred from an animal having an inactivated uMUP complex.
- an animal bred from a dam which is homozygous for the inactivated uMUP complex may be used in behavioural studies.
- Behavioural studies include determining the role of uMUPs in chemical communication and assessment of the effects of removal of this line of communication.
- behavioural studies include, but are not limited to, studies of growth performance, reproductive success, sexual and parental behaviour such as motherpup recognition, male aggression and same sex aggression. Behavioural studies also include investigation into the recognition of male scent by females and vice versa, and also the recognition of particular individuals.
- transgenic animal used in establishing the molecular mechanism underlying MHC associated odours.
- the transgenic animal used in establishing the molecular mechanism underlying MHC associated odours is homozygous for the inactivated uMUP complex, but a heterozygous animal may also be used.
- the transgenic animal used in establishing the molecular mechanism underlying MHC associated odours may also be an animal bred from an animal having an inactivated uMUP complex. In particular an animal bred from a dam which is homozygous for the inactivated uMUP complex may be used in establishing the molecular mechanism underlying MHC associated odours.
- a further aspect of the invention provides the use of transgenic animals according to the invention to identify agents which affect animal behaviour.
- the transgenic animal used in identifying agents which affect animal behaviour is homozygous for the inactivated uMUP complex, but a heterozygous animal may also be used.
- the transgenic animal used in identifying agents which affect animal behaviour may also be an animal bred from an animal having an inactivated uMUP complex. In particular an animal bred from a dam which is homozygous for the inactivated uMUP complex may be used in identifying agents which affect animal behaviour.
- Such agents may be agents which, for example, attract or deter animals or which stimulate or reduce aggression.
- the agents may be, for example, organic compounds, proteins or inorganic compounds.
- Transgenic animals produced according to the invention which are homozygous for an inactivated uMUP complex are hypoallergenic.
- the use of such animals is also provided by the present invention.
- Hypoallergenic means that the animal produces much fewer allergens, which cause an allergic reaction, than wild-type animals.
- hypoallergenic animal for use in any activity wherein a human comes into contact with the animal, or with a uMUP produced by the animal, is particularly beneficial.
- Such animals are especially useful in laboratories, animal breeding centres and animal houses, where humans come into frequent and regular contact with animals or their allergens, often several times a day.
- humans may be exposed to animal allergens, for example through ventilation or contact with materials, without direct contact with the animals.
- humans develop allergies to the animals, a large proportion of which is likely to be caused by uMUP secretion.
- Such allergic reactions could be prevented by using hypoallergenic animals.
- Hypoallergenic animals could also be kept as pets.
- hypoallergenic animal according to the invention may be used in any procedure during which a human comes into contact with an animal or its allergens, for example, research, teaching, testing, breeding and supply of animals, animal maintenance, etc.
- a transgenic animal wherein the uMUP cluster is flanked by LoxP sites or other sites capable of recombining to delete the intervening uMUP cluster in response to the presence of ere recombinase or another recombinase.
- the uMUP cluster flanked by the LoxP sites or other equivalent sites can be deleted by contacting the sites with ere recombinase or another equivalent recombinase.
- the ere recombinase or equivalent recombinase can be controlled so that it is only expressed in particular tissues of the animal, e.g., in only liver tissue.
- the transgenic animal according to the second aspect of the present invention also expresses ere recombinase or an equivalent recombinase.
- the recombinase is inducibly expressed or is tissue specifically expressed.
- a liver specific knockout could be generated. This can be done by placing LoxP sites on either side of the uMUP cluster to be deleted (see Strategy 2 discussed herein), then making a mouse, then crossbreeding this mouse with one that expresses ere recombinase, for example in the liver. This results in liver specific deletion of the uMUP cluster owing to recognition of the two LoxP sites by ere recombinase which is only expressed in the liver. Methods using this approach are well established (Lewandoski et al, Nature Reviews Genetic, 2: 743-755, 2001).
- the present invention also provides an embryonic stem cell wherein the uMUP complex is flanked by LoxP sites or equivalent sites capable of recombining to delete the uMUP complex in response to the presence of a recombinase.
- the embryonic stem cell comprises a gene encoding the recombinase operably linked to control elements enabling the recombinase gene to be inducibly or tissue specifically expressed.
- the embryonic stem cell is a non-human stem cell, more preferably a rodent (e.g. mouse or rat) embryonic stem cell.
- Figure 1 shows schematically 2 alternative methods of deleting the uMUP complex: method (1) comprises using a single targeting vector that spans the half megabase uMUP region; method (2) comprises using two separate vectors that target each end of the uMUP region and insert LoxP sites in the same orientation, wherein unique short PCR amplifiable tags are inserted at each side of the LoxP sites.
- Figure 2 shows the use of two vectors, and shows the result of the vectors being integrated either cis or trans.
- Figure 3 shows schematically a single vector (pMupsTVl) for deleting the uMUP complex.
- Figure 4 shows restriction digests demonstrating the correct structure of pMupsTVl.
- a lanes 1 and 2 show pMUPSTVl digested with CIaI and Fsel. This excises the Tscot homology arm, which is 3.8 kb long. The brighter band towards the top of the gel is the rest of the vector (9kb approx).
- Lane 3 is blank, lane 4 is the IKb+ DNA size ladder (Invitrogen). The arrow highlights the 4kb band.
- B lane 5 contains the IKb+ DNA size ladder (Invitrogen).
- Lane 6-9 All plasmids shown in lanes 6-9 contain 2 Notl sites, which excise the insert from the pUC57 plasmid backbone.
- Lane 6 contains the original pMups plasmid obtained from Genscript. Note 2 bands, the pUC57 band (2.7kb) and a 4.7kb band that contains the ZFP37 homology, the selection cassette and assorted linkers containing various restriction sites.
- Lane 7 contains pMUPSTcf ⁇ c, which also includes the Tscot arm (3.8 kb). Therefore, the band excised by Notl is now 8.5kb.
- Lanes 8 and 9 contain pMUPSTVl. The insert size is now 10.1kb, following the addition of the TKl cassette (see fig2).
- C lanes 10, 11 and 12 contain pMUPSTVl cut with Pad and Xhol. This excises the TKl cassette (approx 1.7kb). The upper band represents the rest of the construct (11.1kb). Lane 13 contains the IKb+ DNA size ladder (Invitrogen). Note: These figures were obtained from a 0.75% agarose gel. Resolution is accurate between 0.5 and 6-7kb. Bands above this size may migrate higher than they should, especially if more concentrated than the DNA ladder.
- Figure 5 shows schematically a successful targeting event between the region of mouse chromosome 4 and pMUPs TVl.
- a successful targeting results in the loss of the uMUP cluster.
- the positive selection cassette is flanked by LoxP sites, an option remains to remove this using ere recombinase at a later date. This could be useful in order to eliminate the possibility that the selection cassette contributes to any phenotype resulting from the targeting.
- Arrows depict the direction of transcription of the two genes flanking the uMUP cluster.
- Successful integration of the targeting vector should not disrupt the expression of these genes in any way.
- Figure 6 shows schematically the outcome of successful targeting using two vectors, followed by Cre mediated recombination between LoxP sites, resulting in the loss of the uMUP cluster.
- Recombination between any of the 4 LoxP sites is possible, selection for successful loss of the uMUP cluster may be accomplished via the addition of 5 ' and 3' segments of an HPRT minigene between the outermost LoxP sites and the relevant ZFP37 and Tscot homologies.
- Successful recombination between the two outermost LoxP sites results in selectable expression of Hprt, if the ES cell line used for targeting is Hprt negative (e.g., HMl).
- uMUPs and their bound ligands are essential involatile components for the recognition of the sex and identity of conspecif ⁇ cs or their scent marks, and whether uMUPs are the proteins responsible for the binding and release of MHC-associated odours, requires the ability to manipulate the presence or absence of uMUPs and their bound ligands at source.
- the invention relates to the creation of transgenic animals, especially mice that do not express uMUPs by gene knockout (referred to as uMUP " ). Unlike other genes such as those comprising the MHC, eliminating the expression of uMUPs is unlikely to have functional consequences beyond scent communication.
- the ability to eliminate uMUP expression allows the inventors to test the importance of learnt associations between uMUP-ligand complexes and volatiles alone. Normal wild-type mice inevitably will be exposed to their own and maternal uMUPs during rearing but, by eliminating uMUP expression genetically, the inventors are able to control the exposure of mice to uMUPs completely, even from birth. The inventors are thus able to address both the fundamental molecular basis of sex and identity information in scents and how experience influences the way that this information is used.
- uMUP 7 males can be applied, for example, to examine the dynamics of territorial scent marking, use of these marks to modulate competitive interactions and the overall outcome in terms of competitive advantage and reproductive success for males that invest in uMUPs.
- Many uMUPs ligands in males also have VNO-mediated reproductive priming effects on females, accelerating puberty, synchronising oestrus and blocking pre-implantation pregnancy in unfamiliar females.
- the availability of uMUP "7" mice would allow further investigation of the role of uMUPs in delivering priming signals to the VNO and the importance of learnt associations between volatile and involatile components in reproductive priming.
- MUPs are expressed in several tissues, including salivary, mammary and lachrymal glands and the liver; the proteins synthesised in the liver are secreted into the bloodstream and filtered by the kidney to be released in urine.
- the urinary MUP (uMUP) genes in particular have been unambiguously mapped to a tightly linked unit on chromosome 4, mapped by hamster:mouse somatic cell hybrids (Krauter et al. 1982; Bennett et al. 1982; Bishop et al.
- the current version of the C57BL/6J mouse genome sequence has loci distributed over several chromosomes that share sequence identity (at protein and nucleotide levels) with MUPs. However, detailed examination of these loci confirms that uMUPs are encoded in a cluster on chromosome 4. This is entirely consistent with previous genomic analyses, mapping and linkage studies. Other MUP-like sequences elsewhere in the mouse genome encode MUPs that are expressed in other tissues (e.g. chromosome 7: salivary/mammary glands) or which show weak homology to uMUPs (chromosome 2).
- the latter sequences contain structural motifs, in particular the N- terminally located GXW triad, which suggests that these genes encode lipocalins, but they are clearly not uMUPs.
- the chromosome 4 homologies all map to the middle of contig NT_039262 and extend over a lMbp region from 59-60Mbp, which is in very- good agreement with the original proposal of a 720kb region proposed by Bishop et al. (1982). This region of chromosome 4 is syntenic with a 750kb region of rat chromosome that has been shown by FISH to encode the equivalent rat ⁇ 2u proteins (McFadyen & Locke 2000).
- the inventors' analysis of the C57BL/6J genome indicates 15 regions of homology that include the urinary MUP genes 1, 3, 4 and 5; some of the other MUP-like sequences may be pseudogenes. Exhaustive analysis of this region of chromosome 4 has confirmed that there are no genes in this region other than MUPs or pseudogenes. Thus, deletion of the entire IMbp will be effective in ablating every uMUP gene, and carries no risk of deletion of other passenger genes that might interfere with the knockout phenotype.
- mice which have the uMUP complex deleted.
- C57BL/6J (B6) has the advantage of full genomic map and sequence availability and is a potentially better described mouse strain for behavioural studies.
- 129Sv/Ev is the best available for gene knockout studies with numbers of well proven and characterised ES cell lines.
- the full genomic sequence for the 129 strain uMUP region of chromosome 4 is not, however, available.
- the chromosome 4 uMUP region is flanked by Tscot — a putative thymic stromal co- transporter gene mapping between nucleotides 59173225 and 59183155 and the zinc- finger gene Zfp37 mapping between 60517046 and 60535864 bp.
- the first uMUP gene is MUP4 at 59224905-59228764 thus leaving an intergenic region of about 41kb.
- the last locus in this region with a sequence homology to the MUPs is the ensemble predicted novel transcript ENSMUSG00000044500 mapping at 60410982-60414792 bp which therefore leaves an intergenic region before Zfp37 of 38kb.
- MUP homologies are found in an approximately IMbp region (1253439bp) from 59224905-60478344bp (MUP4 and LOC381531/MUP3 represent the 5' most and 3' most homologies), using the numbering system from the contig NT_039262.2 flatfile. MUP4 is found at 59224905-59228764bp and LOC381531 at 60475343-60478344. Using this method of assessment, the flanking genes, Tscot and Zfp37, are positioned at 59173225-59183155bp and 60517046-60535930bp respectively.
- an embryonic stem cell from the relevant species e.g. mouse, which has an intact uMUP complex
- One or more targeting vectors as detailed in strategies one and two below are provided.
- the vectors are introduced into the embryonic stem cell under conditions to allow removal of the uMUP complex to create an embryonic stem cell with no uMUP complex.
- the embryonic stem cell is then introduced into a blastocyst which is implanted into the uterus of a pseudo pregnant female. The blastocyst is allowed to gestate and is later delivered.
- the resulting animal is then bred with other such animals and selected for homozygosity and heterozygosity of the deleted uMUP complex.
- the animal is tested for germline transmission of the uMUP deletion via PCR and/or Southern Blotting.
- Strategy 1 A single targeting vector with long homology arms embracing the full deletion is used. These long arms increase the homologous recombination frequency, but may make Southern blot analysis difficult. As this is a large deletion, the cell clones which have integrated the vector are first be screened by interphase FISH for the uMUP region. Clones in which there is only a single interphase hybridisation will be further screened by FISH on metaphase chromosome spreads to confirm that only a single chromosome 4 retains the MUP complex. This is the fastest strategy.
- strategy 1 involves the use of a single replacement vector pMupsTVl (see Figure 3).
- the vector comprises a puromycin resistance cassette, associated with an internal ribosome entry site (IRES) that will only work if it integrates downstream of an existing gene promoter and is transcribed as part of an mRNA.
- the IRES then allows independent translation of the puromycin resistance gene (Puro).
- This IRESpuro resistance cassette is flanked by two arms bearing homology to the two genes flanking the uMUP cluster on either side. One arm is homologous to the 3 'end of the ZFP37 gene. Correct integration of one side of the vector into this site will ensure transcription and translation of the resistance cassette, generating puromycin resistant cells (see Figure 5).
- This selection strategy is known as promoter trapping, further examples of this technique are described elsewhere (Stanford et ah, 2001).
- the other arm is homologous to a region flanking Tscot, the gene on the other side of the uMUP cluster.
- This arm of the vector is longer (3.8kb) and is therefore more likely to integrate via homologous recombination.
- TKl thymidine kinase gene
- Random integration of the vector should not result in the removal of TKl from the end of the Tscot homology arm, thereby rendering the cells sensitive to gancyclovir.
- Puro and gancyclovir resistant cells should have integrated the vector arms at the correct sites, thereby deleting the intervening segment containing the uMUP cluster (see Figure 5).
- screening of embryonic stem (ES) cell DNA via long range PCR, Southern blot and optionally fluorescence in situ hybridization (FISH) is undertaken.
- the 3.8kb Tscot homology arm was amplified using a long range PCR strategy (Invitrogen, Accuprime Pfx DNA polymerase), incorporating CIaI and Fsel sites into the PCR primers, and cloned into the Genscript plasmid (pMups) asymmetrically using the CIaI and Fsel sites.
- the negative selection cassette (the thymidine kinase gene, TKl) was then amplified from a previously successful vector (Mansergh et ah, 2005) using a similar PCR strategy incorporating Pad and Xliol sites into the PCR primers. These sites were then used to incorporate TKl into this vector.
- Sequence data for the design of the synthesized portion of the plasmid was supplied by us to Genscript. Sequence of the Zfp37 homology arm was obtained from NCBI, while sequence of the IRESpuro cassette was based on that purchased from Clontech with the plasmid pIRESpuro3, but modified to include 2 LoxP sites. These were included such that on successful integration and excision of the uMUP cluster, the selection cassette can be removed using Cre recombinase. Selection cassettes can sometimes contribute to the phenotypes of mouse models if positioned in a region of DNA which has subsequently proven to be of functional importance.
- Strategy 2 Two targeting vectors with different selection cassettes are used, one to integrate at each end of the complex and both bearing a LoxP site. Similar strategies have been used to induce translocations and/or create large scale deletions previously (Ciavatta et al. 1995, Mills and Bradley, 2001, Smith et al. 1995, 2002). Long and shorter arms of homology will allow conventional PCR and Southern blot screening and verification of correct integration. The targeting will be carried out serially. Successfully double-targeted clones may have the two vectors integrated either in cis or trans but because the full contiguous sequence is known they will be in the same orientation.
- Cre mediated recombination between the two LoxP sites will lead to deletion of the uMUP complex on one chromosome if they are in cis and the other chromosome will be unaltered. If, however, they are in trans the result of recombination will be a chromosomal translocation with deletion on one product and reduplication on the other.
- the two may be readily experimentally distinguished by including PCR-able tag sequences in the targeting constructs.
- a tag sequence on the distal side of the LoxP site may be left on the deleted chromosome in order to facilitate genotyping when breeding the mice (see Figure 2).
- the vector on the ZFP37 side of the uMUP cluster may be based on pMUPSTVl above.
- the 3.8 kb Tscot homology arm will be replaced by 2-3kb homology to further
- the vector will then integrate on that side of the uMUP cluster. It contains LoxP sites and will engineer puromycin resistance into correctly targeted ES cells.
- a further LoxP containing vector may then be designed to integrate on the Tscot side, and may comprise a neomycin resistance cassette. A method for performing such a strategy is shown in Figure 6.
- Mup +/- ES cells will be generated via standard methodology.
- a uMUP cluster knockout can be generated from heterozygous ES cells following crossbreeding of heterozygous Fl progeny.
- the rationale for the generation of homozygous ES cells is that a large market for uMUP null animals in terms of standard research usage.
- One of the current reasons for the worldwide increase in use of laboratory mice is the generation of thousands of genetically engineered mouse (GEM) models by investigators who are using these to unravel the functions of the genome. Rather than using time consuming breeding methods to generate uMUP null GEM mice, it would be easier for investigators to engineer their models using pre-isolated uMUP null (-/-) ES cells.
- GEM genetically engineered mouse
- Embryos can be isolated from uMUP null mice and null ES cell lines established via standard methods (Joyner et al., 2000).
- transgenic animals that express no uMUPs could have another, much more general application to research using laboratory mice.
- Lipocalins are the main cause of laboratory animal allergy (Virtanen et al. 1999), a very common health problem among those working with laboratory animals such as mice and rats. Approximately one-third of exposed people develop symptoms, and about 10% develop asthma (reviewed by Gordon & Preece 2003). Exposure to laboratory animals is one of the top three causes of occupational asthma in the UK (Bush 2001).
- Urinary MUPs, or equivalent urinary proteins termed a2u globulins in rats, are by far the most prevalent allergens (Schumaker 1980; Wood 2001).
- Eliminating uMUP production would considerably reduce the production of allergens by laboratory mice at source, reducing the risk of sensitisation for the majority of workers and reducing the level of environmental controls required to prevent laboratory animal allergy. However, this would eliminate an important component of the mouse communication system. Before developing such strains, it is essential to confirm that eliminating uMUPs would neither significantly impact the welfare of animals kept under laboratory conditions nor compromise production traits. In fact, loss of uMUP-mediated communication may not cause significant problems under laboratory conditions and, indeed, might help to reduce problems associated with aggression. Inbred laboratory mice are genetically identical and already unable to discriminate individuals using genetically-determined scents (Boyse et al. 1987; Nevison et al. 2000).
- uMUPs may be important for recognition between the sexes in breeding stock, but these are externally voided cues that could be provided artificially for the brief period required, using urine or soiled bedding from a strain with normal uMUP expression. No abnormalities were reported in an inbred strain with a spontaneous mutation (now lost) causing very low expression of uMUPs (Duncan et al. 1988).
- uMUPs One of the main functions of uMUPs is in competitive signalling among males.
- Competitive aggression and territorial defence can cause considerable welfare problems in small cages, resulting in social stress, wounding and sometimes fatal injuries among males of outbred strains or of relatively aggressive inbred strains such as BALB/c (Jennings et al. 1998). This is also likely to increase variability among experimental subjects, but the alternative of single housing induces isolation stress and can be prohibitively expensive. Since uMUPs provide the basis of territorial scent marks and bind volatile male pheromones that stimulate aggression, eliminating uMUP production could reduce the signals that promote aggression between males.
- uMUP knockout within inbred strains can be assessed to provide a ann i inniittiiaall i innddiiccaattiioonn o off t thhee o ovveerraallll e effffeeccttss o off u uMMUUPP '' '' "" o orn normal behavioural and reproductive functioning for later studies of uMUP function.
- Heterozygous Fl uMUP +/" mice on B6 and 129/SvEv genetic backgrounds may be crossed within strain to generate F2 and F3 uMUP +/+ , uMUP "7" and uMUP +/” offspring on each inbred background.
- Weaned offspring may be genotyped.
- Initial assessment of numbers of each genotype and sex at weaning, weaning weights and home cage behaviour can be used to check for any reduction in viability and development or altered behaviour among uMUP " " offspring.
- phenotypic differences may be accentuated by differences in behaviour or growth between offspring according to genotype or by genetic similarity between offspring and dam.
- Offspring from heterozygous pairings will also experience uMUPs produced by mothers and by littermates.
- Homozygous F2 and F3 from heterozygous litters may be selected and inbred to produce F3 and F4 litters of homozygous uMUP " ⁇ or uMUP +/+ controls, resulting in four separate genetic lines varying in background (B6 or 129/SvEv) and uMUP production.
- B6 or 129/SvEv background
- offspring will only have experience of their own homozygous genotype.
- Additional F2 and F3 heterozygous uMUP +/" offspring may be crossed with wild mice to examine the functional significance of uMUPs against a normal heterogeneous genetic background (see below).
- Urine samples may be obtained from F2 offspring of both sexes post-weaning (uMUP +/+ , uMUP +/' and uMUP " ' " ). Overall expression of uMUPs may be assessed by quantitative western blotting (specific antisera already available). Most (>90%) of 2-sec butyl 4-5 dihydrothiazole ('thiazole') and 3-4 dehydro-exo-brevicomin ('brevicomin') are uMUP -bound. The absence of uMUPs could therefore lead to these ligands being expressed in normal levels, but not associated with protein. Alternatively, the uMUPs might, en route from the liver, serve as protective vehicles for the pheromones.
- Urine samples (lO ⁇ l) are deposited on replicate 1.5cm dia. glass fibre disks that are suspended and open to air. At different times after deposition, a disk is removed, ligands are extracted and analysed by GC/MS.
- the rate of release of thiazole and brevicomin is nionotonic and can usually be explained as a single or double exponential (depending on whether ligands are protein bound).
- mice will be investigated by (i) painting uMUP " " mice with urine from normal mice of their own sex, particularly around the anogenital area, (ii) applying urine from normal mice of the opposite sex to the nares of paired uMUP "7" mice, or (iii) housing the mice on substrate soiled by normal mice (from one or both sexes).
- mice that are not investing in uMUP production might increase in mice that are not investing in uMUP production, particularly among post-pubertal males when both growth rate and urinary uMUP production are maximised.
- Body weight may be measured weekly from weaning until asymptotic adult weight is reached among F3 and F4 mice of both sexes.
- Normal behaviour and welfare may be assessed among mice weaned into single sex groups of three of the same genotype by video recording behaviour in the home cage over 24h (shortly after weaning, once adult and aged 3-4mo).
- Activity rhythms; propensity to develop stereotypical behaviour patterns; proportion of time spent chewing at cage bars, which reflects an attempt to escape from the home cage and is considerably increased among animals under poor social or environmental home cage conditions Hurst et al. 1996; Lewis 2003; Lewis & Hurst 2004
- duration of exploratory behaviour and the type and duration of different social behaviours may all be compared.
- Aggression may be decreased among uMUP "7" mice if either the production of male pheromones that stimulate aggression, or sensitivity to these scents, is reduced.
- Adult males of B6 and related strains show relatively low levels of aggression when males have lived together since weaning but this is elevated if males are reintroduced after single housing, are exposed to females or female scents, or home cages are contaminated with scents from other strains. Less is known about aggression within 129/Sv strains, but these are reported to show very similar behaviour to BALB strains with relatively high levels of aggression (Lathe 1996; Le Roy et al. 2000). Differences in aggression within trios of uMUP " " or control adult males on each genetic background when males are familiar cagemates and when unfamiliar males are introduced after one week of single housing may be compared.
- mice Olfactory sensitivity to urinary scent stimuli. Two factors might reduce the general olfactory sensitivity and interest of mice in social scent stimuli, since the development of neuronal sensory pathways is often dependent on early sensory experience and responses to social stimuli often require prior experience.
- the extent of investigatory interest when mice encounter (i) urine from uMUP "7' mice of the same strain, (ii) urine from uMUP ";" mice of a different strain, (iii) urine from control mice of the same strain, (iv) urine from control mice of a different strain may be checked. Responses may be measured during lOmin tests in a clean arena. Mice also show a characteristic pattern of investigatory behaviour on meeting an unfamiliar individual, even when these are from the same inbred strain. The duration and type of investigatory behaviour in interactions between different same sex dyads of unfamiliar uMUP " " and control mice may be examined.
- uMUPs and their bound ligands are responsible for the innate recognition of conspecific male scent by females.
- a comparison may be made between the reaction of a female mouse to the urine of a wild-type or wild-derived male mouse and a uMUP -/- male mouse.
- females use involatile uMUP type to recognise the cagemate, they will prefer the sister with the familiar uMUP type to the unfamiliar uMUP type when able to contact the scent source, but not in response to volatiles only (which should be equally similar to the sister cagemate). Females are then exposed to contact with scents from both unfamiliar sisters so that they can learn the association between involatile uMUPs and volatile scents. If females recognise the familiar uMUP pattern of their cagemate and update the association with volatiles, they prefer scent from the sister with the familiar uMUP type to the unfamiliar uMUP type even when presented with volatiles only.
- mice To further test the ability of mice to track environmentally-induced changes in the volatile profiles of individuals through a learnt association with uMUPs, we manipulate the volatile scents associated with familiar cagemates by adding artificial odours to their urine scents.
- mice To test whether MHC-associated odours result from the differential binding and release of volatiles by fragments of MHC proteins, or are due to MHC-associated differences in volatile metabolites that are bound and released by uMUPs, we test the ability of mice to discriminate between volatiles released from the protein fraction of urine when donors differ only according to MHC (termed H2 in mice) and either express uMUPs or are uMUP '7" .
- uMUP "7" mice crossed onto a wild-derived background enables us to further address questions concerning the role of uMUPs in competitive scent signalling among male mice. These require relatively simple behavioural experiments and can be carried out making use of the animals according to the invention.
- Gerlai R (1996) Gene-targeting studies of mammalian behavior: is it the mutation or the background genotype? Trends Neurosci 19: 177-81.
- Hurst JL (1993) The priming effects of urine substrate marks on interactions between male house mice, Mus musculus domesticus. Anim Behav 45: 55-81. Hurst JL, Barnard CJ, et al. (1996) Housing and welfare in laboratory rats - Time-budgeting and pathophysiology In single-sex groups. Anim Behav 52: 335-360.
- Nevison CM CM, Barnard CJ, et al. (2000) The consequences of inbreeding for recognising competitors. Proc R Soc B 267: 687-694. Nevison CM, Hurst JL, et al. (1999) Strain-specific effects of cage enrichment in male laboratory mice (Mus musculus). Animal Welfare 8: 361-379.
- Wood RA (2001) Laboratory animal allergens. liar J 42: 12-16.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Molecular Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/720,730 US20090276864A1 (en) | 2004-12-03 | 2005-12-05 | Transgenic animals with reduced major urinary protein production |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0426650.8 | 2004-12-03 | ||
| GBGB0426650.8A GB0426650D0 (en) | 2004-12-03 | 2004-12-03 | Transgenic animals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2006059145A2 true WO2006059145A2 (en) | 2006-06-08 |
| WO2006059145A3 WO2006059145A3 (en) | 2006-10-05 |
Family
ID=34044071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB2005/004674 Ceased WO2006059145A2 (en) | 2004-12-03 | 2005-12-05 | Transgenic animals with reduced major urinary protein production |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20090276864A1 (en) |
| GB (1) | GB0426650D0 (en) |
| WO (1) | WO2006059145A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6715568B2 (en) * | 2015-01-22 | 2020-07-01 | 公益財団法人東京都医学総合研究所 | A model animal for depression that causes sleep disorders |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002031151A2 (en) * | 2000-10-13 | 2002-04-18 | Incyte Genomics, Inc. | Lipocalins |
-
2004
- 2004-12-03 GB GBGB0426650.8A patent/GB0426650D0/en not_active Ceased
-
2005
- 2005-12-05 WO PCT/GB2005/004674 patent/WO2006059145A2/en not_active Ceased
- 2005-12-05 US US11/720,730 patent/US20090276864A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006059145A3 (en) | 2006-10-05 |
| US20090276864A1 (en) | 2009-11-05 |
| GB0426650D0 (en) | 2005-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jaramillo et al. | Altered striatal synaptic function and abnormal behaviour in Shank3 exon4‐9 deletion mouse model of autism | |
| Nonet et al. | Caenorhabditis elegans rab-3 mutant synapses exhibit impaired function and are partially depleted of vesicles | |
| De Boer et al. | A mouse model for the basal transcription/DNA repair syndrome trichothiodystrophy | |
| D'Adamo et al. | Deletion of the mental retardation gene Gdi1 impairs associative memory and alters social behavior in mice | |
| Bark et al. | Developmentally regulated switch in alternatively spliced SNAP-25 isoforms alters facilitation of synaptic transmission | |
| Su et al. | Neurobeachin is essential for neuromuscular synaptic transmission | |
| Mark et al. | Delayed postnatal loss of P/Q-type calcium channels recapitulates the absence epilepsy, dyskinesia, and ataxia phenotypes of genomic Cacna1a mutations | |
| CN104450602B (en) | Non-human mammal animal model of neuropsychiatric disease and preparation method and application thereof | |
| Campbell et al. | Mutation of a novel gene results in abnormal development of spermatid flagella, loss of intermale aggression and reduced body fat in mice | |
| Khuchua et al. | Deletion of the N-terminus of murine map2 by gene targeting disrupts hippocampal ca1 neuron architecture and alters contextual memory | |
| Mayeux-Portas et al. | Mice lacking the cell adhesion molecule Thy-1 fail to use socially transmitted cues to direct their choice of food | |
| Huebner et al. | Mice lacking the nuclear pore complex protein ALADIN show female infertility but fail to develop a phenotype resembling human triple A syndrome | |
| Jacobs et al. | Importance of the GluN2B carboxy-terminal domain for enhancement of social memories | |
| AU2005302854B2 (en) | Prematurely ageing mouse models for the role of DNA damage in ageing and intervention in ageing-related pathology | |
| Maas et al. | Identification of spontaneous mutations within the long‐range limb‐specific Sonic hedgehog enhancer (ZRS) that alter Sonic hedgehog expression in the chicken limb mutants oligozeugodactyly and silkie breed | |
| Bianchi et al. | Forebrain deletion of αGDI in adult mice worsens the pre-synaptic deficit at cortico-lateral amygdala synaptic connections | |
| Chen et al. | Jxc1/Sobp, encoding a nuclear zinc finger protein, is critical for cochlear growth, cell fate, and patterning of the organ of corti | |
| US20090276864A1 (en) | Transgenic animals with reduced major urinary protein production | |
| McRory et al. | Syntaxin 1A is required for normal in utero development | |
| Yang et al. | Impaired motor coordination in mice that lack punc | |
| US8198507B2 (en) | Transgenic or recombinant non-human mammals and their uses in screening psychoactive medicines | |
| Balu et al. | Behavioral and physiological characterization of PKC-dependent phosphorylation in the Grin2a∆ PKC mouse | |
| JP3711367B2 (en) | Knockout animals | |
| JP2020089332A (en) | Non-human genetically modified animal and method for producing the same | |
| JP4412530B2 (en) | Hairless mice or hairless rats with mutations in the TRPV3 gene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 05813931 Country of ref document: EP Kind code of ref document: A2 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 05813931 Country of ref document: EP Kind code of ref document: A2 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 11720730 Country of ref document: US |